William Blair Issues Negative Forecast for Repligen Earnings

Repligen Co. (NASDAQ:RGEN) – Stock analysts at William Blair decreased their Q1 2025 earnings per share (EPS) estimates for shares of Repligen in a note issued to investors on Monday, March 10th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings per share of $0.32 for the quarter, down from their prior forecast of $0.33. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q3 2025 earnings at $0.42 EPS, FY2025 earnings at $1.67 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.30 EPS.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%.

Several other analysts have also recently commented on the company. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Royal Bank of Canada lifted their price target on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $181.00.

Repligen Trading Down 12.0 %

Shares of NASDAQ RGEN opened at $136.99 on Tuesday. The company has a market cap of $7.68 billion, a price-to-earnings ratio of -268.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen has a 12-month low of $113.50 and a 12-month high of $200.23. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock’s 50 day simple moving average is $157.09 and its 200 day simple moving average is $148.51.

Institutional Trading of Repligen

A number of institutional investors and hedge funds have recently modified their holdings of RGEN. Signaturefd LLC lifted its stake in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new position in Repligen during the 4th quarter valued at $29,000. Raiffeisen Bank International AG acquired a new position in Repligen during the 4th quarter valued at $29,000. Resources Management Corp CT ADV acquired a new position in Repligen during the 3rd quarter valued at $37,000. Finally, Quarry LP raised its stake in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.